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Osteoarthritisa b s t r a c t
Leptin and vascular cell adhesion molecules-1 (VCAM-1) are two important mediators in obesity-
related osteoarthritis, while the molecular mechanism linking leptin to VCAM-1 production is still
obscure. Here we show that leptin upregulates VCAM-1 mRNA and protein levels in a time- and
dose-dependent manner. Mechanistically, leptin induces VCAM-1 promoter activity by increasing
the expression of C/EBP-a and facilitating its binding to a newly identiﬁed element in the VCAM-1
gene. Gain or loss of function studies reveal a regulatory role of C/EBP-a on VCAM-1 expression.
Finally, elevated plasma leptin level correlates to increased C/EBP-a and VCAM-1 production in
chondrocytes from obese mice.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Osteoarthritis (OA), a most common rheumatic disease, is
characterized by irreversible destruction of the joint cartilage. Bio-
chemical, genetic and mechanical factors contribute to the onset
and progress of this disorder. Lots of studies focus on the mechan-
ical role of obesity on OA [1], while abnormal adipokines from dys-
functional adipose tissues are emerging as relevant factors which
affect the cartilage structure [2,3].
Leptin, a most important adipose-derived hormone, is originally
identiﬁed as a controller of food intake through its receptors [4]. It
also has been reported that leptin signaling functions in chronic
inﬂammation [5], insulin resistance [6], and tumorogenesis [7].
Specially, leptin is recently characterized as a linker between
obesity and OA [8]. Mechanistically, leptin induces cartilage degra-
dation by upregulating or activating matrix metalloproteinases
[9,10] and proinﬂammatory cytokines, including IL-6, IL-8 and so
on [11].
Vascular cell adhesion molecules-1 (VCAM-1), an inducible
surface glycoprotein that belongs to immunoglobulin genesuperfamily (IgSF) [12], was newly identiﬁed as a predictor of se-
vere OA of the hip and knee joints [13]. It has been reported that
VCAM-1 gene was transcriptionally regulated in a cell type-depen-
dent manner [13]. Located near the transcriptional initiation site
are several sequences that corresponded to previously deﬁned
transcription factor binding sites for NF-jB, GATA family [14],
AP-1 [15] and Ets class [16]. Most recently, VCAM-1 was reported
as a target of leptin [17], while the regulatory mechanism is still
not fully characterized. In the present study, we identiﬁed a novel
transcription factor CCAAT-enhancer-binding protein-a (C/EBP-a)
responsible for leptin-induced VCAM-1 production by binding to
the promoter region of VCAM-1, providing a possible molecular
mechanism linking obesity to OA.
2. Materials and methods
2.1. Mice
All animal studies were conducted in accordance with the
guidelines for the care and use of laboratory animals and were ap-
proved by the Animal Care and Use Committee. Male C57BL/6 mice
were purchased from the experimental animal center of the Third
Military Medical University. The mice were housed ﬁve per cage
supplied with a normal rodent diet or high fat diet (HFD) in a path-
ogen-free facility with 12-h light, 12-h dark cycle. 12-week old
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lation. The mice with 16-week HFD or normal diet were used for
plasma leptin assay (#MOB00, R&D) and protein assay of primary
chondrocytes.
2.2. Isolation of primary mouse and human chondrocytes
Primary mouse articular chondrocytes were isolated by dissec-
tion of the tibial plateaus and femoral condyles of the male C57BL/
6 mice at 4 months of age. The articular cartilage was carefully
peeled off with a scalpel under a dissecting microscope to avoid
disruption of the subchondral bone. The cartilage was
subsequently digested with 2 mg/ml clostridial collagenase
(#17101-015, Invitrogen) at 37 C for 2 h and then plated in mono-
layer culture. The chondrocytes from 5 mice were pooled as one
sample upon isolation. The primary chondrocytes were directly
subjected to protein assay or cultured in Dulbecco’s modiﬁed Ea-
gle’s medium supplemented with 10% fetal calf serum, 1% gluta-
mine, 100 units/ml penicillin, 50 g/ml Streptomycin (Invitrogen),
maintained and proliferated at 37 C in the presence of 5% CO2
for 7 days prior to the initiation of each experiment.
Normal human articular cartilage samples were obtained from
the knee joints of patients undergoing total knee replacement sur-
gery (with permission from the patients and the local ethics com-
mittee). The primary human chondrocytes were obtained
following the protocol for primary mouse chondrocytes.
2.3. Protein extraction and immunoblotting
Cell proteins were extracted with RIPA Lysis Buffer and quanti-
ﬁed by the BCA kit (Roche, USA). The extracted proteins were sep-
arated by 8% or 10% SDS–PAGE and transfered to a polyvinylidene
diﬂuoride membrane. The membrane was then used for immuno-
blotting with the antibodies [Anti-GAPDH (#2118, Cell signaling),
Anti-C/EBP-a (sc-365318X, Santa Cruz), Anti-VCAM-1 (ab134047,
Abcam)].
2.4. Realtime qPCR
Total RNA was extracted using the Trizol reagent (Invitrogen)
according to the manufacture’s protocol. Reverse transcription
and quantitative PCR were performed as described previously
[18]. All the primers used for PCR are available upon request.
2.5. ChIP assay
ChIP assay was used to study leptin-induced interaction be-
tween the C/EBP-a protein and VCAM-1 promoter DNA in mouse
and human chondrocytes. The detailed protocol was described pre-
viously [19]. Brieﬂy, the primers for C/EBP-a protein binding site in
mouse VCAM-1 promoter were designed as: forward: 50-AGA-
CCTACAGAGGCATTT-30, reverse: 50-GAGATGAATTGACAACCA-30.
The primers for C/EBP-a protein binding site in human VCAM-1
promoter were designed as: forward: 50-TGGGCAAGCATTTTG-
CAAGGCCTT-30, reverse: 50-CTTTTCCCCCCAGTGAAGTGCCTT-30.
Ampliﬁcation conditions were denaturation at 94 C for 30 s,
annealing at 60 C for 30 s, and extension at 72 C for 30 s for 38
cycles, and the expected products were 100 bps.
2.6. Gain or loss of function studies
Mouse or human C/EBP-a overexpression was performed by
transfecting the chondrocytes with a constitutive expression plas-
mid speciﬁc for mouse (MR205482, ORIGENE) or human C/EBP-a
(RC218955, ORIGENE). Mouse or human endogenous C/EBP-awas knocked down by using a commercial siRNA kit
(#SI00948311, QIAGEN) or (sc-37047, Santa Cruz), respectively.
2.7. Molecular cloning experiments
The experiments for DNA constructs, cell transfection, reporter
gene assays and site-directed reporter gene mutation were per-
formed as described previously [19].
2.8. Statistics
Data are generated as mean ± S.D. Comparisons were performed
using ANOVA for multiple groups or Student’s t test for two groups.
P < 0.05 is considered statistically signiﬁcant.
3. Results
3.1. Leptin induces mouse VCAM-1 production
To investigate the effect of leptin on VCAM-1 expression in
chondrocytes, the primary mouse chondrocytes were treated with
leptin in different concentrations and time points. As shown in
Fig. 1, leptin stimulated VCAM-1 mRNA and protein levels in a
time- and dose-dependent manner. The optimal condition of leptin
for VCAM-1 stimulation is 500 nM for 24 h.
3.2. Leptin-induced VCAM-1 promoter activity via a novel C/EBP-a
binding site
As leptin displayed stimulation on VCAM-1 production in
mRNA and protein levels, we speculated that transcriptional mech-
anism would involve in this process. Therefore, a 3050-bp (3000
to +50) DNA fragment harboring the mouse VCAM-1 promoter was
cloned into pGL4-basic vector (PV1). Further, a series of mutated
plasmids harboring different regions of VCAM-1 promoter (PV2–
PV6) were constructed (Fig. 2A). Reporter gene assay indicated that
promoter region 1000 to 500 bps is required for leptin-induced
VCAM-1 transcriptional activity (Fig. 2B). Interestingly, the se-
quences 850 to 600 bps in mouse VCAM-1 gene are highly con-
served, comparing to the sequences 950 to 700 bps in human
VCAM-1 gene according to DNA sequence alignment (data not
shown), which indicates that some important cis-acting elements
locate in this region.
To identify the involved transcriptional factors in leptin-in-
duced VCAM-1 transcription, we searched the putative transcrip-
tion factor binding sites (TFBS) in DNA sequences from 850 to
600-bp in mouse VCAM-1 gene by using an online software
(http://alggen.Isi.upc.es). Several elements including a p53 biding
site (683–689), a AP-2-a binding site (637 to 642) and a C/
EBP-a binding site (617 to 623) got high scores. To identify
whether those elements are functional in leptin-induced VCAM-1
expression, we performed site-directed mutations of those ele-
ments, respectively (Fig. 2C). Reporter gene assay experiments ver-
iﬁed that the core sequences of C/EBP-a (but not p53 or AP-2-a)
binding element (AATTGAG), is largely required for leptin-induced
VCAM-1 promoter activity (Fig. 2D).
3.3. C/EBP-a involvement in leptin-induced VCAM-1 production
To conﬁrm the regulatory role of C/EBP-a on VCAM-1 expres-
sion, we overexpressed or downregulated C/EBP-a in primary
mouse chondrocytes, and determined the VCAM-1 expression. As
expected, constitutive expression of C/EBP-a increased VCAM-1
expression in the levels of protein (Fig. 3A) and mRNA (Fig. 3D).
Consistently, small interfering RNA (si-RNA)-mediated C/EBP-a
Fig. 1. Leptin induces VCAM-1 expression in primary mouse chondrocytes. Leptin stimulated mRNA (A) and protein (B) levels of VCAM-1 in a time-dependent manner as
indicated. The primary mouse chondrocytes were treated with leptin (500 nM) for 0, 12, 24 and 36 h, and then subjected to mRNA and protein assay by realtime qPCR and
Western blotting, respectively (A and B). Leptin induced mRNA (C) and protein (D) levels of VCAM-1 in a dose dependent manner. The primary mouse chondrocytes were
treated with leptin for 24 h at different concentrations (0, 50, 100 and 500 nM). In A and C, values not sharing a common superscript letter differ signiﬁcantly (P < 0.05, n = 5).
Fig. 2. Leptin induces VCAM-1 promoter activity via a C/EBP-a element in primary mouse chondrocytes. (A) A schematic depiction of different mouse VCAM-1 promoter
regions cloned into pGL4-basic plasmid. The constructs were designed as PV1–PV6 as indicated. (B) Promoter region 1000 to 500-bp was required for leptin-induced
luciferase activity of VCAM-1 in primary mouse chondrocytes according to the transfection and reporter gene assay (⁄⁄⁄P < 0.005, n = 5). (C) The predicted C/EBP-a, AP-2a and
p53 binding sites in the VCAM-1 promoter were mutated, respectively. A predicted C/EBP-a binding site (triangle) located at 617/623, a AP-2a binding site (square)
located at 637 to 642, and a p53 element (circle) located at 683 to 689 upstream of the transcription starting site of mouse VCAM-1 gene. The constructs PV1-mut1,
PV1-mut2 and PV1-mut3 were designed from PV1 with the mutated elements of C/EBP-a, AP-2a and p53, respectively. (D) Mutation of the C/EBP-a binding site decreased
leptin-induced promoter activity in primary mouse chondrocytes according to the transfection and reporter gene assay (⁄⁄⁄P < 0.005, n = 5).
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C/EBP-a mRNA and protein levels were stimulated by leptin treat-
ment. The stimulation of leptin on VCAM-1 production was largely
rescued by C/EBP-a knockdown (Fig. 3C and F). Signiﬁcantly, lossor gain of function of C/EBP-a in primary human chondrocytes
deceased or increased VCAM-1 expression in protein levels,
respectively (Fig. S1A and B). Small interfering RNA-mediated C/
EBP-a knockdown largely abolished leptin-induced expression of
Fig. 3. C/EBP-a mediates leptin-induced VCAM-1 production in primary mouse chondrocytes. (A) Primary mouse chondrocytes were transfected with a plasmid expressing
constitutive active C/EBP-a (0.4 lg/ml medium) or empty vector pCDNA3.1 as control for 24 h. The untreated cells were used as negative control (NC). Cell lysates were
subjected to Western blotting assay for C/EBP-a, VCAM-1 and GAPDH as internal control (⁄⁄P < 0.01, n = 3). (B) Primary mouse chondrocytes were transiently transfected with
a small interfering RNA speciﬁc for mouse C/EBP-a (si-C/EBP-a) at a ﬁnal dose of 20 nmol/ml or a scramble RNA as control (si-NC) for 36 h. The untreated cells were collected
as negative control (NC). Cell lysates were analyzed as described in (A) (⁄⁄P < 0.01, n = 3). (C) Primary mouse chondrocytes were transiently transfected with si-C/EBP-a
(20 nmol/ml) or si-NC (20 nmol/ml) for 12 h, and then supplied with leptin (500 nM) for another 24 h. Cell lysates were analyzed as described in (A) (⁄⁄P < 0.01, n = 3). (D)
Primary mouse chondrocytes were treated as described in (A), and collected for the assay of C/EBP-a and VCAM-1 mRNAs by Realtime qPCR (⁄⁄P < 0.01, n = 5). (E) Primary
mouse chondrocytes were treated as described in (B), and collected for the assay of C/EBP-a and VCAM-1 mRNAs by Realtime qPCR (⁄⁄P < 0.01, n = 5). (F) Primary mouse
chondrocytes were treated as described in (C), and collected for the assay of C/EBP-a and VCAM-1 mRNAs by Realtime qPCR (⁄⁄P < 0.01, n = 5).
Fig. 4. Leptin induces C/EBP-a binding to VCAM-1 promoter. (A) Primary mouse
chondrocytes were collected for ChIP assay. Cell lysates were immunoprecipitated
with mouse anti-C/EBP-a antibody or IgG as control. (B) Primary mouse chondro-
cytes were transiently transfected with or without si-C/EBP-a (20 nmol/ml) or si-
NC (20 nmol/ml) for 12 h, and then supplied with leptin (500 nM) for another 24 h.
Cell lysates were subjected to ChIP assay as described in (A). Experiments in A and B
were replicated for three times and representative results were displayed.
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indicates that induction of leptin on C/EBP-a-dependent VCAM-1
expression is a common mechanism.
To further verify whether C/EBP-a protein directly bind to the
predicted binding site in mouse VCAM-1 gene promoter, ChIP as-
say was performed. As shown in Fig. 4A, C/EBP-a could bind with
the predicted elements located at617 to623. The binding activ-
ity could be potentiated by leptin treatment, and siRNA-mediated
C/EBP-a knockdown attenuated this effect (Fig. 4B). Likewise,
bioinformatical prediction indicated that a potential C/EBP-a bind-
ing site (AATTGGG) located at 792 to 786 in the conserved
promoter region of human VCAM-1 gene. ChIP assay veriﬁed that
leptin treatment could enhance C/EBP-a binding to the aforemen-
tioned binding site in human VCAM-1 gene (Fig. S1D).
3.4. Increased plasma leptin level correlated to increased VCAM-1
production in the mouse chondrocytes from diet-induced obese (DIO)
mice
In order to correlate the regulatory mechanism in vitro to phys-
iopathological signiﬁcance in vivo, high-fat diet-induced obese
Fig. 5. Increased plasma leptin level is parallelized with increased C/EBP-a and VCAM-1 production in the mouse chondrocytes from diet-induced obese (DIO) mice. (A)
Plasma leptin levels increased in the mice on a standard high fat diet for 16 weeks (⁄⁄⁄P < 0.005, n = 5, compared with the age-matched lean mice). (B) DIO mouse-derived
chondrocytes displayed increased C/EBP-a and VCAM-1 protein levels. (C) Statistic analysis of the results in B (⁄⁄P < 0.01, n = 3). (D) Increased binding of C/EBP-a to VCAM-1
promoter in DIO mouse-derived chondrocytes. (E) Statistic analysis of the results in D (⁄⁄P < 0.01, n = 5).
Fig. 6. Proposed molecular mechanism for leptin-mediated obesity-related osteo-
arthritis. Plasma leptin level increases in obesity, which activates C/EBP-a and/or
other possible transcription factors like NF-jB binding to VCAM-1 promoter to
promote VCAM-1 production in chondrocytes. Finally, increased VCAM-1 produc-
tion aggravates obesity-related osteoarthritis (The solid arrow-indicated ﬂow is
veriﬁed in this work and the dotted arrow-indicated ﬂow comes from previous
studies.).
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increased (Fig. 4A) correlating to elevated C/EBP-a and VCAM-1
production in primary chondrocytes from DIO mice, as compared
with the lean mice (Fig. 4B and C). To conﬁrm the aforementioned
mechanism, interaction between C/EBP-a protein and VCAM-1
promoter DNA was determined by ChIP assay. The relative DNA
binding activity of C/EBP-a signiﬁcantly increased by 1.5-fold in
DIO mice-derived chondrocytes comparing to the ones form the
lean mice (Fig. 5D and E).
4. Discussion
Obesity-related Osteoarthritis is a most common rheumatic
disease, with increased proinﬂammatory cytokine production and
immune cell inﬁltration in the joints. Thus, extravasation of leuko-
cytes from circulating blood to inﬂamed tissue is crucial in inﬂam-
matory process and this complex event is regulated by VCAM-1
[20]. Blockade of VCAM-1 notably inhibited the binding and
recruitment of leukocytes into inﬂamed joints [21,22]. VCAM-1
has been identiﬁed as a predictor of severe OA of the hip and knee
joints [13]. Thus, it is very important to explore the regulatory fac-
tors of VCAM-1.
Chondrocytes are important resource of the cytokines or
chemokines [23] and play a very crucial role in maintaining the car-
tilage structure. VCAM-1 is one of the cytokines expressed by chon-
drocytes [24], and could bemodulated by leptin-induced JAK2, PI3K
and AMPK signaling [17]. Here we described a novel transcriptional
mechanism for leptin-mediated VCAM-1 production.
In previously studies, VCAM-1 was reported to be regulated by
some transcriptional factors via the cis-acting elements which are
located in the proximal region upstream of transcriptional binding
site of VCAM-1 gene [14–16,25]. Here we identiﬁed a novel C/EBP-
a binding site (AATTGAG) locating at 617 to 623 in the mouse
VCAM-1 gene promoter. However, mutation of this element could
not fully rescue leptin’s induction on VCAM-1 promoter activity
(Fig. 2A and B), indicating that some other well-identiﬁed cis-act-
ing elements like NF-jB and AP-1 in the proximal region might
also contribute to leptin-induced VCAM-1 promoter activity, be-
cause those transcriptional factors could be activated by leptin in
other cell types [26,27]. Therefore, further studies are required to
elucidate this hypothesis.To explore the physiopathological signiﬁcance, we ﬁnally con-
ﬁrmed the molecular mechanism in diet-induced obesity mice
and found that elevated plasma leptin level was correlated to in-
creased C/EBP-a, VCAM-1 production and interaction between C/
EBP-a protein and VCAM-1 promoter DNA in primary chondro-
cytes. We propose that obesity-related leptin or other cytokines in-
crease the transcriptional activity of C/EBP-a or other transcription
factors like NF-jB to promote VCAM-1 production in chondrocytes.
The over-produced VCAM-1 would promote the progression of
obesity-related OA (Fig. 6).
Taken together, leptin induces VCAM-1 production by facilitat-
ing C/EBP-a binding to its corresponding binding site in VCAM-1
gene in mouse chondrocytes. Our ﬁndings provide a possible
molecular mechanism linking obesity to OA and shed light on
the new strategy for therapeutic intervention of obesity-related
OA.
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.
2014.02.032.
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